Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ELVN Stock Forecast 2025-2026
$22.45
Current Price
$1.29B
Market Cap
Buy 9
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ELVN Price Targets
+131.6%
To High Target of $52.00
+71.5%
To Median Target of $38.50
+47.0%
To Low Target of $33.00
ELVN Price Momentum
+8.3%
1 Week Change
+2.5%
1 Month Change
-9.3%
1 Year Change
-0.2%
Year-to-Date Change
-25.2%
From 52W High of $30.03
+68.8%
From 52W Low of $13.30
📊 TOP ANALYST CALLS
Did ELVN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Enliven is one of their latest high-conviction picks.
Latest ELVN Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, ELVN has a bullish consensus with a median price target of $38.50 (ranging from $33.00 to $52.00). The overall analyst rating is Strong Buy (9.8/10). Currently trading at $22.45, the median forecast implies a 71.5% upside. This outlook is supported by 9 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Colleen Kusy at Baird, projecting a 131.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ELVN Analyst Ratings
9
Buy
0
Hold
0
Sell
ELVN Price Target Range
Low
$33.00
Average
$38.50
High
$52.00
Current: $22.45
Latest ELVN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ELVN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 2, 2025 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $48.00 |
| Jun 16, 2025 | Goldman Sachs | Salveen Richter | Buy | Initiates | $37.00 |
| Jun 16, 2025 | Baird | Colleen Kusy | Outperform | Maintains | $52.00 |
| May 16, 2025 | Jones Trading | Soumit Roy | Buy | Maintains | $27.00 |
| May 15, 2025 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $40.00 |
| Mar 21, 2025 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $39.00 |
| Dec 13, 2024 | BTIG | Justin Zelin | Buy | Initiates | $42.00 |
| Nov 15, 2024 | Baird | Colleen Kusy | Outperform | Maintains | $40.00 |
| Oct 31, 2024 | Jones Trading | Soumit Roy | Buy | Initiates | $36.00 |
| Oct 1, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $37.00 |
| Sep 9, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Initiates | $37.00 |
| Jun 11, 2024 | Baird | Colleen Kusy | Outperform | Initiates | $32.00 |
| Apr 9, 2024 | Mizuho | Salim Syed | Buy | Initiates | $34.00 |
| Mar 29, 2023 | Jefferies | Eun Yang | Buy | Initiates | $27.00 |
| Mar 3, 2023 | TD Cowen | Outperform | Initiates | $0.00 |
Enliven Therapeutics, Inc. (ELVN) Competitors
The following stocks are similar to Enliven based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Enliven Therapeutics, Inc. (ELVN) Financial Data
Enliven Therapeutics, Inc. has a market capitalization of $1.29B with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -31.3%.
Valuation Metrics
Market Cap
$1.29B
Enterprise Value
$695.44M
P/E Ratio
0.0x
PEG Ratio
-9.2x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+26.3%
Current Ratio
21.1x
Debt/Equity
0.2x
ROE
-31.3%
ROA
-21.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Enliven Therapeutics, Inc. (ELVN) Business Model
About Enliven Therapeutics, Inc.
What They Do
Develops novel therapeutic solutions for diseases.
Business Model
The company focuses on precision medicine by creating targeted therapies for genetic disorders and oncology. It generates revenue through the development and commercialization of these innovative treatments, addressing unmet medical needs in the healthcare sector.
Additional Information
Enliven Therapeutics is positioned within the biotechnology sector, attracting investor interest due to its commitment to innovative healthcare solutions and the potential for significant advancements in patient care.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
65
CEO
Mr. Samuel S. Kintz M.B.A.
Country
United States
IPO Year
2023
Website
www.enliventherapeutics.comEnliven Therapeutics, Inc. (ELVN) Latest News & Analysis
Latest News
Quick Summary
Enliven Therapeutics closed its public offering of 9.92 million shares at $19.66 each, including 1.52 million additional shares. Pre-funded warrants for 1.78 million shares were also offered.
Why It Matters
Enliven Therapeutics' successful stock offering raises capital for development, signaling growth potential and impacting share performance, investor sentiment, and market confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
ELVN-001 shows a cumulative MMR rate of 47% and 32% of patients achieving MMR at 24 weeks, with a favorable safety profile. A conference call is scheduled for June 13 at 1:30 p.m. ET.
Why It Matters
The reported MMR rates for ELVN-001 suggest strong efficacy compared to past treatments, enhancing its investment appeal in the oncology sector. Favorable safety data further supports this potential.
Source: PRNewsWire
Market Sentiment:
Neutral
Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
1 month ago
Quick Summary
Enliven Therapeutics (Nasdaq: ELVN) has launched a $200 million underwritten public offering of common stock and pre-funded warrants for investors.
Why It Matters
Enliven Therapeutics' $200 million public offering signals potential dilution of shares, impacting stock prices and investor sentiment regarding its financial health and growth prospects.
Source: PRNewsWire
Market Sentiment:
Neutral
Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
1 month ago
Quick Summary
Enliven Therapeutics (Nasdaq: ELVN) announced a public offering of 8.39 million shares at $19.66 each and pre-funded warrants for 1.78 million shares at $19.659 each.
Why It Matters
Enliven Therapeutics' public offering may dilute existing shares but also raises capital for development, impacting future growth potential and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Enliven Therapeutics (Nasdaq: ELVN) will present at TD Cowen's 6th Annual Oncology Innovation Summit on May 27, 2025, at 1:00 p.m. ET.
Why It Matters
Enliven Therapeutics' participation in key investor conferences signals potential for increased visibility and interest, which could impact stock performance and investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
1 month ago
Quick Summary
Enliven will present Phase 1 ENABLE trial data for ELVN-001 in CML at EHA 2025, showing a 44% cumulative MMR rate. The company has $290M in cash, ensuring funding through late 2027.
Why It Matters
Positive trial results for ELVN-001 in CML indicate potential for market approval, while a strong cash position ensures funding for ongoing operations, enhancing investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ELVN Stock
What is Enliven Therapeutics, Inc.'s (ELVN) stock forecast for 2026?
Based on our analysis of 8 Wall Street analysts, Enliven Therapeutics, Inc. (ELVN) has a median price target of $38.50. The highest price target is $52.00 and the lowest is $33.00.
Is ELVN stock a good investment in 2026?
According to current analyst ratings, ELVN has 9 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $22.45. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ELVN stock?
Wall Street analysts predict ELVN stock could reach $38.50 in the next 12 months. This represents a 71.5% increase from the current price of $22.45. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Enliven Therapeutics, Inc.'s business model?
The company focuses on precision medicine by creating targeted therapies for genetic disorders and oncology. It generates revenue through the development and commercialization of these innovative treatments, addressing unmet medical needs in the healthcare sector.
What is the highest forecasted price for ELVN Enliven Therapeutics, Inc.?
The highest price target for ELVN is $52.00 from Colleen Kusy at Baird, which represents a 131.6% increase from the current price of $22.45.
What is the lowest forecasted price for ELVN Enliven Therapeutics, Inc.?
The lowest price target for ELVN is $33.00 from at , which represents a 47.0% increase from the current price of $22.45.
What is the overall ELVN consensus from analysts for Enliven Therapeutics, Inc.?
The overall analyst consensus for ELVN is bullish. Out of 8 Wall Street analysts, 9 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $38.50.
How accurate are ELVN stock price projections?
Stock price projections, including those for Enliven Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 13, 2025 10:26 PM UTC